Carl Zeiss Meditec

Reasonably good Q2, despite underlying challenges/risks

13/05/22 -"Despite the supply-chain challenges, CZM reported a reasonably good set of Q2 21/22 results. Both segments reported double-digit growth and order intake was impressive. Unlike most of the MedTech ..."

PDF page sample
Pages
65
Language
English
Published on
13/05/22
Download
You may also be interested by these reports :
14/11/25
Sonova reported decent H1 results, with sales aligning with the company-compiled consensus. However, normalised EBITA did not meet expectations due ...
13/11/25
The Q3 results were somewhat ahead of expectations, and the 2025 guidance was maintained this time, after two downgrades earlier this year. This, ...
07/11/25
GN’s Q3 results fell short of expectations. Sales growth in Hearing and Gaming was nearly counterbalanced by weakness in Enterprise. Profitability ...
06/11/25
DiaSorin’s Q3 results did not meet expectations, with all segments underperforming except for immunodiagnostics. As a result, management has lowered ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO